Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
One Percent Rule Checklist For Safer Forex Trading Risk 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
SOUTH SAN FRANCISCO, Calif., April 20, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2017 financial results on Thursday, May 4, 2017, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, May 4, 2017, at 4:30 p.m. (ET)/1:30 p.m. (PT) to discuss the company's financial results and provide a general business update.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 4178195.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.
CONTACT: Heather Rowe Investor Relations 415-365-5737 [email protected]
